PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7862540

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
MICHAEL KLICHINSKY	06/14/2021
NICHOLAS G. MINUTOLO	06/15/2021
NICHOLAS R. ANDERSON	06/15/2021

RECEIVING PARTY DATA

Name:	CARISMA THERAPEUTICS INC.
Street Address:	3675 MARKET STREET
Internal Address:	STE 200
City:	PHILADELPHIA
State/Country:	PENNSYLVANIA
Postal Code:	19104

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17477494

CORRESPONDENCE DATA

Fax Number: (617)502-5002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6172485000

Email: patentdocket@choate.com

Correspondent Name: CHOATE HALL & STEWART, LLP TWO INTERNATIONAL PLACE Address Line 1:

Address Line 4: BOSTON, MASSACHUSETTS 02110

ATTORNEY DOCKET NUMBER:	2012851-0107
NAME OF SUBMITTER:	MELISSA M. ADAMS, PHD, JD
SIGNATURE:	/Melissa M. Adams/
DATE SIGNED:	03/23/2023

Total Attachments: 8

source=2012851-0107 Joint Assignment#page1.tif source=2012851-0107 Joint Assignment#page2.tif source=2012851-0107 Joint Assignment#page3.tif

> **PATENT** REEL: 063076 FRAME: 0691 507815408

source=2012851-0107 Joint Assignment#page4.tif source=2012851-0107 Joint Assignment#page5.tif source=2012851-0107 Joint Assignment#page6.tif source=2012851-0107 Joint Assignment#page7.tif source=2012851-0107 Joint Assignment#page8.tif

> PATENT REEL: 063076 FRAME: 0692

Docket Number: 2012851-0100

COMBINED JOINT ASSIGNMENT & DECLARATION

A. <u>ASSIGNMENT</u>

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Michael Klichinsky	Philadelphia, Pennsylvania
2. Nicholas G. Minutolo	Philadelphia, Pennsylvania
3. Nicholas R. Anderson	Philadelphia, Pennsylvania

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

NOVEL CONSTRUCTS FOR CHIM	IERIC ANTIGEN RECEPTORS; and
prepared for filing in the United S	tates Patent and Trademark Office; or
identified by United States Applic illed in the United States Patent and Tradema	
identified by International Patent A filed on June 4, 2021	Application No. PCT/US21/35991 _; and
x and is also aware of the following	priority applications:
Application No.	Filed
63/082584	September 24, 2020
63/044934	June 26, 2020

WHEREAS, Carisma Therapeutics Inc. (hereinafter "ASSIGNEE"), having a usual place of business at 3675 Market Street, Ste 200, Philadelphia, Pennsylvania 19104, desires to acquire or confirm an interest therein;

63/034873

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us hereby confirms, agrees, and/or declares that:

June 4, 2020

- 1. I have sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application;
- 2. My sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by me had this sale, assignment and transfer not been made;
- 3. This Assignment, being of my entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;
- 4. I, or my executor(s) and/or administrator(s) will execute upon request any other lawful documents and likewise will perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts I know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;
- 5. I hereby authorize ASSIGNEE or its attorneys or agents to insert the correct application number(s) and/or filing date(s) into this assignment document, if appropriate;
- 6. I hereby appoint ASSIGNEE as my common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

Page 2 of 8

2012851-0100

- 7. I hereby request the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;
- 8. I hereby covenant with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by me, and that full right to convey the same as herein expressed is possessed by me.

Page 3 of 8

2012851-0100

B. <u>DECLARATION (37 CFR 1.63)</u>

As a below named inventor, I hereby declare that:

This declaration is directed to the patent application entitled:

NOVEL CONSTRUCTS FOR CHIMERIC ANTIGEN RECEPTORS; and

attached hereto or prepared for filing in the United St	tates Patent and Trademark
Office; or	
identified by United States Application No. filed in the United States Patent and Trademark Office on	; or
x identified by International Patent Application No. filed on June 4, 2021	PCT/US21/35991

The above-identified application was made or authorized to be made by me.

I believe that I am the original inventor or an original joint inventor of a claimed invention in the application.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

I have reviewed and understand the contents of the application, including the claims and am aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Page 4 of 8

2012851-0100

gen.	DocuSigned by:		
Signature:	Michael Elichinsky	Date:	6/14/2021
_	Michael Klichinsky DocuSigned by:	-	
	Susannah Asseue 12284B46BB6D4CO		
Witness Sign	lature:	_	
	Susannah Ayscue		
Witness Nam	ie (printed):	_	
	DocuSigned by:		
Witness Sign	Elena Petrossian		
williess sign	1ature2409398760914C5	-	
*****	Elena Petrossian		
Witness Nam	ie (printed):		

DocuSigned by:		
Signature: Mcholas Minutolo	Date:	6/15/2021
Nicholas G. Minutolo		
ر DocuSigned by:		
Witness Signature: Sujannah Aysene		
Susannah Ayscue		
Witness Name (printed):		
DocuSigned by:		
Witness Signature: Elena Petrossian		
Elena Petrossian		
Witness Name (printed):		

Docusigi	-		
Signature: Mchola	is K. Anderson	Date:	6/15/2021
Nichola	s R. Anderson DocuSigned by:		
	Susannah Ayscue 		
Witness Signature:	D2284B46BB6D4C0		
Witness Name (prin	Susannah Ayscue ted):		
	DocuSigned by:		
Witness Signature:	Elena Petrossian 2409398760914C5		
Withoss Signature.	Elena Petrossian		
Witness Name (prin			

The ASSIGNEE hereby acknowledges and accepts the foregoing assignment.

The undersigned (w	whose title is supplied below) is authorized to ac	t on beh	alf of the
ASSICENIEFE	Wilton		6/17/2021
C : , }	EABB18B432	Date:	-, , -
Name (printed):	Fom Wilton		
Title (printed):	СВО		

Page 8 of 8

2012851-0100

PATENT REEL: 063076 FRAME: 0700